Personalized dosing may boost chemo power in stubborn testicular cancers

NCT ID NCT00864318

First seen Apr 22, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This study tested a two-step high-dose chemotherapy plan for 101 people with germ cell tumors that returned or didn't respond to initial treatment. The approach used paclitaxel and ifosfamide first, then carboplatin and etoposide, with carboplatin doses tailored to each patient to reduce side effects like hearing loss. The goal was to see if this personalized dosing could improve complete response rates while keeping toxicity manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU

    Clermont-Ferrand, 63003, France

  • CHU

    Strasbourg, 67091, France

  • Centre Antoine Lacassagne

    Nice, 06050, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Paul Papin

    Angers, 49933, France

  • Hopital St André

    Bordeaux, 33075, France

  • Hopital TENON

    Paris, 75970, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Claudius Regaud

    Toulouse, 31052, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Paoli Calmette

    Marseille, 13273, France

  • Institut Val d'aurelle

    Montpellier, 34298, France

Conditions

Explore the condition pages connected to this study.